Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group,
fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to
criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,
(DSM-5).